Facebook Twitter LinkedIn YouTube Instagram

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

GSK3915393

Status:

Phase 2

Condition:

Idiopathic Pulmonary Fibrosis

Intervention Type:

Oral Drug

Funder Type:

Industry

Drug Details

GSK3915393 is a small molecule that acts by targeting transglutaminase-2 (TG2).

Study Purpose

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in participants with IPF.

Find a Clinical Trial